Co-Authors
This is a "connection" page, showing publications co-authored by DIMPY KOUL and JOHN FREDERICK DE GROOT.
Connection Strength
0.668
-
The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab015.
Score: 0.196
-
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res. 2020 03 15; 26(6):1395-1407.
Score: 0.182
-
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006 Mar; 5(3):637-44.
Score: 0.070
-
Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther. 2005 Nov; 4(11):1681-8.
Score: 0.068
-
Neuronal differentiation drives the antitumor activity of mitogen-activated protein kinase kinase (MEK) inhibition in glioblastoma. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad132.
Score: 0.059
-
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021 06 01; 23(6):920-931.
Score: 0.050
-
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
Score: 0.043